FDA Commissioner Mark Makary will step down this week after losing a public battle with the Trump administration over a range of health policies. The Johns Hopkins surgeon-turned-regulator became a target of the administration's Make America Healthy Again movement after clashing on vaping restrictions, abortion access and drug pricing initiatives.

Makary's exit follows President Trump's formal approval of his removal last week, ending a turbulent tenure marked by frequent public disagreements with health officials and White House advisors. As a vocal critic of certain FDA processes, he aligned with MAHA advocates who pushed for deregulation in medical devices and pharmaceuticals. His departure signals a potential shift in FDA leadership philosophy.

The commissioner's resignation comes as pharmaceutical and biotech stocks often react to FDA leadership changes, given the agency's power over drug approvals and market access. Investors will now watch who Trump selects as Makary's successor, particularly whether the administration doubles down on MAHA principles or returns to more traditional regulatory approaches. The change also impacts ongoing policy debates around GLP-1 drug pricing and weight-loss medication oversight.